CN108431006A - 酪蛋白激酶1δ在乳腺癌中的治疗靶向 - Google Patents

酪蛋白激酶1δ在乳腺癌中的治疗靶向 Download PDF

Info

Publication number
CN108431006A
CN108431006A CN201680071705.XA CN201680071705A CN108431006A CN 108431006 A CN108431006 A CN 108431006A CN 201680071705 A CN201680071705 A CN 201680071705A CN 108431006 A CN108431006 A CN 108431006A
Authority
CN
China
Prior art keywords
cancer
ck1δ
breast cancer
catenin
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680071705.XA
Other languages
English (en)
Chinese (zh)
Inventor
威廉·R·劳什
德里克·R·达克特
约翰·L·克利夫兰
劳拉·H·罗森伯格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scripps Research Institute
Original Assignee
Scripps Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Institute filed Critical Scripps Research Institute
Publication of CN108431006A publication Critical patent/CN108431006A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201680071705.XA 2015-10-13 2016-10-05 酪蛋白激酶1δ在乳腺癌中的治疗靶向 Pending CN108431006A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562240689P 2015-10-13 2015-10-13
US62/240,689 2015-10-13
PCT/US2016/055436 WO2017066055A1 (en) 2015-10-13 2016-10-05 THERAPEUTIC TARGETING OF CASEIN KINASE 1δ IN BREAST CANCER

Publications (1)

Publication Number Publication Date
CN108431006A true CN108431006A (zh) 2018-08-21

Family

ID=58517824

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680071705.XA Pending CN108431006A (zh) 2015-10-13 2016-10-05 酪蛋白激酶1δ在乳腺癌中的治疗靶向

Country Status (8)

Country Link
US (2) US10603322B2 (enExample)
EP (1) EP3362452A4 (enExample)
JP (1) JP2018538241A (enExample)
CN (1) CN108431006A (enExample)
AU (1) AU2016338639A1 (enExample)
CA (1) CA3001903A1 (enExample)
HK (1) HK1259409A1 (enExample)
WO (1) WO2017066055A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113271962A (zh) * 2018-08-22 2021-08-17 默克专利有限公司 利用靶向TGF-β抑制的三阴性乳腺癌的治疗

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200078387A1 (en) * 2016-12-16 2020-03-12 The Johns Hopkins University Chemical inhibitors against kinases to block telomere elongation in cancer
WO2019145386A1 (en) 2018-01-26 2019-08-01 Roche Innovation Center Copenhagen A/S Oligonucleotides for modulating csnk1d expression
WO2019217421A1 (en) 2018-05-08 2019-11-14 The Scripps Research Institute Small molecule inhibitors of cdk12/cdk13

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140200207A1 (en) * 2013-01-16 2014-07-17 Signal Pharmaceutical Llc Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
US20150274729A1 (en) * 2012-02-29 2015-10-01 The Scripps Research Institute Wee1 degradation inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150274729A1 (en) * 2012-02-29 2015-10-01 The Scripps Research Institute Wee1 degradation inhibitors
US20140200207A1 (en) * 2013-01-16 2014-07-17 Signal Pharmaceutical Llc Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BIBIAN M. ET AL.: "Development of highly selective casein kinase 1d/1e (CK1d/e)inhibitors with potent antiproliferative properties", 《BIOORGANIC & MEDICINAL CHEMISTRY LETTERS》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113271962A (zh) * 2018-08-22 2021-08-17 默克专利有限公司 利用靶向TGF-β抑制的三阴性乳腺癌的治疗

Also Published As

Publication number Publication date
EP3362452A1 (en) 2018-08-22
AU2016338639A1 (en) 2018-05-10
CA3001903A1 (en) 2017-04-20
US10603322B2 (en) 2020-03-31
HK1259409A1 (zh) 2019-11-29
US20200163972A1 (en) 2020-05-28
WO2017066055A1 (en) 2017-04-20
US20180311252A1 (en) 2018-11-01
EP3362452A4 (en) 2019-06-12
JP2018538241A (ja) 2018-12-27

Similar Documents

Publication Publication Date Title
Liu et al. An RFC4/Notch1 signaling feedback loop promotes NSCLC metastasis and stemness
Rosenberg et al. Therapeutic targeting of casein kinase 1δ in breast cancer
Zhou et al. TSPAN1 promotes autophagy flux and mediates cooperation between WNT-CTNNB1 signaling and autophagy via the MIR454-FAM83A-TSPAN1 axis in pancreatic cancer
Zhao et al. Cullin5 deficiency promotes small-cell lung cancer metastasis by stabilizing integrin β1
Wang et al. EZH2-H3K27me3-mediated silencing of mir-139-5p inhibits cellular senescence in hepatocellular carcinoma by activating TOP2A
Wang et al. Direct inhibition of ACTN4 by ellagic acid limits breast cancer metastasis via regulation of β-catenin stabilization in cancer stem cells
Zhang et al. Intrinsic BET inhibitor resistance in SPOP-mutated prostate cancer is mediated by BET protein stabilization and AKT–mTORC1 activation
Hu et al. G9a and histone deacetylases are crucial for Snail2‐mediated E‐cadherin repression and metastasis in hepatocellular carcinoma
Park et al. Inhibition of LEF1-mediated DCLK1 by niclosamide attenuates colorectal cancer stemness
Zhang et al. Demethylzeylasteral inhibits glioma growth by regulating the miR-30e-5p/MYBL2 axis
Tao et al. miR-27b-3p suppresses cell proliferation through targeting receptor tyrosine kinase like orphan receptor 1 in gastric cancer
Xiao et al. FBXW 7 suppresses epithelial‐mesenchymal transition and chemo‐resistance of non‐small‐cell lung cancer cells by targeting snai1 for ubiquitin‐dependent degradation
Clementz et al. NOTCH-1 and NOTCH-4 are novel gene targets of PEA3 in breast cancer: novel therapeutic implications
Zhou et al. WP1066 sensitizes oral squamous cell carcinoma cells to cisplatin by targeting STAT3/miR-21 axis
Tian et al. Downregulation of AZGP1 by Ikaros and histone deacetylase promotes tumor progression through the PTEN/Akt and CD44s pathways in hepatocellular carcinoma
US20200163972A1 (en) Therapeutic Targeting of Casein Kinase 1 Delta in Breast Cancer
Wang et al. CD24 mediates gastric carcinogenesis and promotes gastric cancer progression via STAT3 activation
Ho et al. Inhibition of the H3K9 methyltransferase G9A attenuates oncogenicity and activates the hypoxia signaling pathway
Zhao et al. High expression of GRP78 promotes invasion and metastases in patients with esophageal squamous cell carcinoma
Paul et al. F‐box protein FBXO16 functions as a tumor suppressor by attenuating nuclear β‐catenin function
Wu et al. CRCT1 regulated by microRNA-520 g inhibits proliferation and induces apoptosis in esophageal squamous cell cancer
Wang et al. PRKAR1A is a functional tumor suppressor inhibiting ERK/Snail/E-cadherin pathway in lung adenocarcinoma
Zhao et al. The FTO mediated N6-methyladenosine modification of DDIT4 regulation with tumorigenesis and metastasis in prostate cancer
Wang et al. Cervical Cancer Cell Growth, Drug Resistance, and Epithelial-Mesenchymal Transition Are Suppressed by γ-Secretase Inhibitor RO4929097
Han et al. TIMP3 overexpression improves the sensitivity of osteosarcoma to cisplatin by reducing IL-6 production

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20180821

WD01 Invention patent application deemed withdrawn after publication